8-K: Mangoceuticals Faces Nasdaq Delisting Warning

Mangoceuticals, Inc. received a Nasdaq deficiency notice for failing to maintain a minimum bid price of $1.00 per share.

Summary

• Mangoceuticals, Inc. (MGRX) received a deficiency notification from the Nasdaq Stock Market LLC on February 4, 2026.
• The company is not in compliance with Nasdaq Listing Rule 5550(a)(2) because its common stock bid price closed below $1.00 per share for 30 consecutive business days.
• MGRX has a 180-calendar day period, until August 3, 2026, to regain compliance with the minimum bid price requirement.
• To regain compliance, the bid price for the company's common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days.
• Nasdaq's written notice currently has no effect on the listing or trading of the company's common stock.
• The company intends to actively monitor the closing bid price of its common stock and will consider available options to resolve this listing deficiency.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, reflecting sustained poor market performance and introducing a significant risk of delisting if not resolved. While there's a compliance period, the underlying issue remains concerning.

Positives

• The Nasdaq notice has no immediate effect on the listing or trading of the company's common stock.
• The company has a 180-calendar day period, until August 3, 2026, to regain compliance with the minimum bid price requirement.

Negatives

• Mangoceuticals, Inc. is not in compliance with Nasdaq Listing Rule 5550(a)(2) due to its common stock bid price falling below $1.00 for 30 consecutive business days.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement by August 3, 2026, could lead to the delisting of the company's common stock from The Nasdaq Stock Market LLC.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock and will consider available options to resolve this listing deficiency as appropriate.

Management Comments

• "The Company intends to actively monitor the closing bid price of its common stock and, as appropriate, will consider available options to resolve this listing deficiency."

Industry Context

StockSavvy.ai notes that falling below minimum bid price requirements is a common challenge for smaller-cap companies, particularly in volatile market conditions or after periods of underperformance. Such notices often signal underlying operational or market perception issues that can impact investor confidence.

Stakeholder Impact

• Shareholders face increased risk of delisting, which could lead to reduced liquidity and investor confidence. The stock price may experience further downward pressure.

Next Steps

• Actively monitor the closing bid price of its common stock.
• Consider available options to resolve the listing deficiency.
• Regain compliance by having the bid price close at $1.00 or more for a minimum of 10 consecutive business days by August 3, 2026.

Key Dates

Recommendation

While the Nasdaq deficiency notice is a significant negative, the company has a 180-day period to regain compliance, and the notice does not immediately affect trading. A seasoned investor would likely hold to observe the company's actions and market response during this compliance period, but with a high degree of caution due to the delisting risk and underlying poor stock performance.

Keywords

Mangoceuticals, MGRX, Nasdaq, delisting, minimum bid price, compliance, stock market, SEC filing, 8-K